GlassScriptPhysician profile
Jenna Boutilier
NPI 1154657443
$676.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $48.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $86.56 | 2021 | |
| Paratek Pharmaceuticals, INC. | $73.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $73.23 | 2021 | |
| Abbvie INC. | $52.93 | 2021-2022 | |
| Amarin Pharma, INC. | $34.22 | 2021 | |
| Glaxosmithkline, LLC. | $30.52 | 2021 | |
| Astellas Pharma US INC | $22.71 | 2021 | |
| Mylan Specialty L.P. | $20.60 | 2021 | |
| Merck Sharp & Dohme LLC | $19.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2021 | |
| Novo Nordisk INC | $16.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.45 | 2021 | |
| Lilly USA, LLC | $12.22 | 2021 | |
| Currax Pharmaceuticals LLC | $11.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Boutilier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.